He projects a 10.8% earnings per share (EPS) compound annual growth rate (CAGR) over FY2022-2024 for Vicplas, driven by growth in its medical business.
CGS-CIMB analyst William Tng has initiated coverage on Vicplas with an “add” call and a target price of 27.5 cents.
In a Jan 25 note, Tng points out that the company is tapping into the “medical contract manufacturing space” for growth.
